These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 11147770)
21. The efficacy of topical 0.2% hyaluronic acid gel on recurrent oral ulcers: comparison between recurrent aphthous ulcers and the oral ulcers of Behçet's disease. Lee JH; Jung JY; Bang D J Eur Acad Dermatol Venereol; 2008 May; 22(5):590-5. PubMed ID: 18093111 [TBL] [Abstract][Full Text] [Related]
22. Use of Apremilast for Aphthous Ulcers in a Patient With Behçet’s Syndrome. Saini A; Ferguson C; Salkey K J Drugs Dermatol; 2018 Dec; 17(12):1328-1329. PubMed ID: 30586267 [TBL] [Abstract][Full Text] [Related]
23. The spectrum of mucocutaneous manifestations in Adamantiades-Behçet's disease in Greece. Vaiopoulos G; Konstantopoulou P; Evangelatos N; Kaklamanis PH J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):434-8. PubMed ID: 19758264 [TBL] [Abstract][Full Text] [Related]
24. The IL-8 Gene Polymorphisms in Behçet's Disease Observed in Denizli Province of Turkey. Atalay A; Arıkan S; Ozturk O; Öncü M; Tasli ML; Duygulu S; Atalay EO Immunol Invest; 2016 May; 45(4):298-311. PubMed ID: 27101127 [TBL] [Abstract][Full Text] [Related]
25. Ulcerative colitis followed by the development of Behçet's disease. Kobashigawa T; Okamoto H; Kato J; Shindo H; Imamura T; Iizuka BE; Tanaka M; Uesato M; Ohta SJ; Terai C; Hara M; Kamatani N Intern Med; 2004 Mar; 43(3):243-7. PubMed ID: 15098609 [TBL] [Abstract][Full Text] [Related]
26. Clinical Effect of Non-Thermal CO2 Laser Therapy (NTCLT) on Pain Relief of Oral Aphthous Ulcers of Behçet's Disease. Zand N; Ataie-Fashtami L; Mansouri P; Fateh M; Shirkavand A J Lasers Med Sci; 2021; 12():e72. PubMed ID: 35155157 [No Abstract] [Full Text] [Related]
27. Therapeutic Hotline. Oral allicin in the treatment of Behcet's disease through attenuating oxidative stress: A pilot study in 20 patients with mucocutaneous lesions. Zhong J; Xian D; Xiong X; Liu J Dermatol Ther; 2017 Jan; 30(1):. PubMed ID: 27723197 [TBL] [Abstract][Full Text] [Related]
28. Effects of azithromycin on intracellular cytokine responses and mucocutaneous manifestations in Behçet's disease. Mumcu G; Inanç N; Özdemir FT; Tulunay A; Ekşioğlu-Demiralp E; Ergun T; Direskeneli H Int J Dermatol; 2013 Dec; 52(12):1561-6. PubMed ID: 23879671 [TBL] [Abstract][Full Text] [Related]
29. Anticoagulant and Fibrinolytic Disorders in Patients with Behçet's Disease and Recurrent Aphthous Ulcer. Shang H; Ye JJ; Ji M; Wang FF; Zhu YY; Qi XM Chin J Physiol; 2011 Aug; 54(4):235-40. PubMed ID: 22129821 [TBL] [Abstract][Full Text] [Related]
30. Behçet's disease: A profile of mucocutaneous features. Kerkeni N; Zaraa I; Ayachi J; El Euch D; Mokni M; Ben Osman A Acta Dermatovenerol Alp Pannonica Adriat; 2010; 19(2):11-5. PubMed ID: 20664915 [TBL] [Abstract][Full Text] [Related]
31. Treatment of mucocutaneous manifestations in Behçet's disease with anakinra: a pilot open-label study. Grayson PC; Yazici Y; Merideth M; Sen HN; Davis M; Novakovich E; Joyal E; Goldbach-Mansky R; Sibley CH Arthritis Res Ther; 2017 Mar; 19(1):69. PubMed ID: 28335798 [TBL] [Abstract][Full Text] [Related]
32. Serum lipoprotein (a) levels and Behçet's disease: is there an association? Balik O; Gur G; Lenk N; Artuz F; Alli N Int J Dermatol; 2007 Aug; 46(8):827-9. PubMed ID: 17651165 [TBL] [Abstract][Full Text] [Related]
33. The importance of serum interleukin-20 levels in patients with Behçet's disease. Enecik ME; Mavi B; Yücel Ç; Keskin G; Yıldız M Adv Clin Exp Med; 2018 Oct; 27(10):1391-1395. PubMed ID: 30048054 [TBL] [Abstract][Full Text] [Related]
34. Behçet's disease: minireview with emphasis on oral aspects. Giannetti L; Murri Dello Diago A; Lo Muzio L Minerva Stomatol; 2018 Dec; 67(6):246-249. PubMed ID: 29915169 [TBL] [Abstract][Full Text] [Related]
35. An incomplete form of childhood Behçet's disease treated with infliximab. Caporuscio S; Pranteda G; Nistico S; Maucione T; Canzoni M; Stefani A; Muscianese M; Fanto M; Sorgi M Int J Immunopathol Pharmacol; 2014; 27(3):445-8. PubMed ID: 25280037 [TBL] [Abstract][Full Text] [Related]
36. Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study. Hatemi G; Melikoglu M; Tunc R; Korkmaz C; Turgut Ozturk B; Mat C; Merkel PA; Calamia KT; Liu Z; Pineda L; Stevens RM; Yazici H; Yazici Y N Engl J Med; 2015 Apr; 372(16):1510-8. PubMed ID: 25875256 [TBL] [Abstract][Full Text] [Related]
37. [Mucocutaneous involvement in Behçet's disease]. Touraine R J Mal Vasc; 1988; 13(3):220-1. PubMed ID: 3171404 [TBL] [Abstract][Full Text] [Related]
38. The influence of oral health and psycho-social well-being on clinical outcomes in Behçet's disease. Senusi A; Higgins S; Fortune F Rheumatol Int; 2018 Oct; 38(10):1873-1883. PubMed ID: 30151720 [TBL] [Abstract][Full Text] [Related]
39. A double-blind trial of depot corticosteroids in Behçet's syndrome. Mat C; Yurdakul S; Uysal S; Gogus F; Ozyazgan Y; Uysal O; Fresko I; Yazici H Rheumatology (Oxford); 2006 Mar; 45(3):348-52. PubMed ID: 16263779 [TBL] [Abstract][Full Text] [Related]
40. Clinical features of late-onset Behçet's disease: report of nine cases. Saricaoglu H; Karadogan SK; Bayazit N; Yucel A; Dilek K; Tunali S Int J Dermatol; 2006 Nov; 45(11):1284-7. PubMed ID: 17076707 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]